Dr. Michael Miller is a cardiologist at Penn Medicine with a notable interest in preventive cardiology. He specializes in the prevention of heart disease, focusing on risk assessment, lipid (cholesterol and triglyceride) management and lifestyle modification. He is a lecturer for the Perelman School of Medicine Foundations of Culinary Medicine. He has conducted research on the effects of diet and emotional health on inflammation and vascular function with multiple publications on this topic. Dr. Miller is the author of “Heal Your Heart…” (Penguin Random-House), and co-author of “The American Medical Association Guide to Preventing and Treating Heart Disease (American Medical Association)” and “The Practice of Coronary Disease Prevention” (Lippincott, Williams & Wilkins).
Publications
Miller M, Aggarwal M, Allen K, Bhattacharya R, Dastmalchi LN, Kris-Etherton PM, Klodas E, Mazaffarian D, Ostfeld RJ, Petersen KS, Reddy KR, Ros E, Vinaithirthan V, Freeman AM A Clinician’s Guide for Trending Cardiovascular Nutritional Controversies in 2026 , Journal of the American College of Cardiology Advances: 2026
Gurevitz C, Bhatt DL, Giugliano RP, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Lira Pineda A, Doyle RT Jr, Giugliano G, Mason RP, Tardif JC, Martens FMAC, Ballantyne CM, Budoff MJ, Gibson CM Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT , Eur J Prev Cardiol: 2026
Miller M, Bhatt DL, Brinton EA, Jacobson TA, Steg PG, Ketchum S, Pineda AL, Tardif J-C, Ballantyne CM on Behalf of the Reduce-IT Investigators Icosapent Ethyl Reduces CVD Risk in Cardiovascular-Kidney-Metabolic Syndrome: REDUCE-IT CKM , American Journal of Preventive Cardiology: 2025
Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton E, Dunbar R, Ketchum S, Tardif J-C, Martens F, Ballantyne CM, Szarek M, Mason RP. Cardiovascular Outcomes with Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. , JAHA: Journal of the American Heart Association.: 2025
Hegele RA, Ahmad Z, Ashraf A, Baldassarra A, Brown AS, Chait A, Freedman SD, Kohn B, Miller M, Patni N, Soffer DE, Wamng J, Broder MS, Chang E, Uermilov I, Campos C, Gibbs SN. Development and Validation of Clinical Criteria to Identify Familial Chylomicronemia Syndrome (FCS) in North America. , Journal of Clinical lipidology: 2025
Burrowes SAB, Zisman E, Fantry LE, Bui Q, Wu A, Sorkin J, Miller M, Bagchi S. Changes in Atherosclerotic Cardiovascular Disease Risk Scores in a Predominantly Black Cohort with HIV and Associated Comorbidities: A Preliminary Study. , Cardiology, 150: 2025,194-202
Hegele RA, Ahmad Z, Ashraf A, Baldassarra A, Brown AS, Chait A, Freedman SD, Kohn B, Miller M, Patni N, Soffer DE, Wamng J, Broder MS, Chang E, Uermilov I, Campos C, Gibbs SN Development and Validation of Clinical Criteria to Identify Familial Chylomicronemia Syndrome (FCS) in North America. , J Clin Lipidol : 2024
Burrowes SAB, Zisman E, Fantry LE, Bui Q, Wu A, Sorkin J, Miller M, Bagchi S Changes in Atherosclerotic Cardiovascular Disease Risk Scores in a Predominantly Black Cohort with HIV and Associated Comorbidities: A Preliminary Study. , Cardiology: 2024
Bhatt DL, Bays HE, Miller M, Cain JE 3rd, Wasilewska K, Andrawis NS, Parli T, Feng S, Sterling L, Tseng L, Hartsfield CL, Agollah GD, Mansbach H, Kastelein JJP; ENTRIGUE Principal Investigators. Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. , Nat Med. : 2024
Szarek M, Bhatt DL, Miller M, Brinton E, Jacobson TA, Tardif J-C, Ballantyne CM, Mason RP, Ketchum SB. Pineda AL, Doyle RT, Steg PG, REDUCE-IT Investigators. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. , J Am Coll Cardiol : 2024
